(Date:11/24/2009)... The FBI recently approved the Promega Pow...ipating in or generating DNA records for the Natio...adison, WI USA (PRWEB) -- The FBI recently approve...e by laboratories participating in, or generating ...IS). NDIS currently contains more than seven milli...
(Date:11/24/2009)...vember24/PRNewswire-FirstCall/--Shireplc(LSE:SHP,...lcompany,today,announcedthatithassubmittedaMAAtoth...ompany,senzymereplacementtherapyindevelopment,fort...keting,applicationforvelaglucerasealfathathasbeens...andCanada. , Basedonaglobalsupplyshortageofth...
(Date:11/24/2009)...ly,November24/PRNewswire/--HealthRoboticstodayanno...groupofselected,investors.ThisrecentlyformedToront...csCanada,Inc.andwillmarket,install,andsupport,Heal...sthe,revolutionaryproductofferingsi.v.STATION(TM),...illalsoprovideassistanceonan"asneeded,basis"toitss...
(Date:11/24/2009)...ov.24/PRNewswire-FirstCall/--CellTherapeutics,Inc....21stAnnualPiperJaffrayHealthCareConference.Theconf...eHotel. ,, CTIwillpresentonTuesday,December1at1...ebcastofCTI,spresentationwillbeavailableat www.cel...ayafterwards. , ,PiperJaffrayHealthCareConference...
Breaking Biology Technology:NDIS Approval of Promega PowerPlex Kit Clears Path for More DNA Profiles to be Added to U.S. Database 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 2Shire Submits European Marketing Authorization Application (MAA) for velaglucerase alfa for the Treatment of Type 1 Gaucher Disease 3Health Robotics Continues its Global Expansion With December 09 ASHP's Launch of Joint Venture in Canada 2...Pharma, Inc. (Nasdaq:,GORX) announced today that i...ts of its third fiscal quarter ended December 31, ...ET) with CEO, Mihir Taneja and VP/CFO,Carol Dore-F...erence call,by utilizing the following URL, http:/...?key=PVYY97BW8 thus,avoiding operator assistance ...
... Schering-Plough,Corporation (NYSE: SGP ) today ...on (FDA) has accepted the Peg-IFN (peginterferon a... (sBLA) for review and has,granted Priority Review...h,Stage III melanoma. Schering-Plough submitted it... The Priority Review designation is intended to ex...
...help doctors and clinicians identify best t...ease, BIRMINGHAM, Ala., Jan. 31 Clinical trial r...ation point to the need for more,detailed choleste...nd other,lipids. That,s according to Atherotech, a...xpanded cholesterol test called the VAP (Vertical ...
Other Biology Technology:GeoPharma Announces Third Quarter Conference Call 2FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 2FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 3FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 4FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 5FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma 6Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy 2Atherotech Says Detailed Cholesterol Test Can Help Doctors and Patients Choose Best Therapy 3Murashige and Skoog basal salt solution with Gamborg's B5 vitamins, 10X concentrate from Research Organics, Inc.
...ing allows a high-throuput screening of a biologic...r artifitially induced changes in the expression l... studied, classified and compared to each other, c...tized scanning of the hybridized slides in Agilent...
Rabbit Anti-Esa1 Polyclonal Antibody, Unconjugated from Abcam
Goat Anti-Human RORgamma (S-14) Polyclonal Antibody, Unconjugated from Santa Cruz Biotechnology, Inc.
Biology Products: